Our Science

Larkspur’s targeted protein degraders disrupt key cancer cell fitness pathways that are essential to tumor survival.

Cancer fitness genes drive pathways that create a survival advantage for malignant cells beyond proliferative mechanisms. These targets are conditionally essential in stress conditions. Larkspur’s degraders target these genes to make cancer cells more susceptible to competition, physiological cell death, and killing mechanisms.

Spotlight on LRK-4189:

LRK-4189 is a first-in-class targeted protein degrader of PIP4K2C, a lipid kinase associated with poor outcomes in multiple cancers, including microsatellite stable (MSS) colorectal cancer (CRC). PIP4K2C is hijacked by cancer cells to increase their fitness and is conditionally essential in cancer-driven stress.

 

Why targeted protein degradation?

Larkspur discovered that effective targeting of PIP4K2C requires degradation, rather than conventional inhibition.

 

By rewiring tumor-intrinsic pathways, LRK-4189 triggers cell death through loss of intrinsic stress adaptions and subsequent metabolic failure.

 

LarkX, our proprietary machine-learning-enabled gene signature platform, identifies pathways with cancer cell-intrinsic stress adaptations.

Larkspur’s clinical development focuses on biomarker-driven cancer patient cohorts to achieve early proof-of-concept.

Our first-in-class pipeline programs have opportunities across multiple cancers, with our lead asset, LRK-4189, targeting MSS colorectal cancer initially.

Lead Discovery
Lead Optimization
Ind-Enabling
Phase 1

LRK-4189

First-in-class PIP4K2C protein degrader; PIP4K2C is a key cellular fitness pathway that enables cancer cell survival under stress

Pin1 Degrader

Novel therapy targeting Pin1 to modulate fibroblasts in cancer and fibrosis

TIM-1 Program

The TIM-1 target is now being pursued as part of a Larkspur Biosciences / Alloy Therapeutics joint venture, Tiburon Therapeutics